Frequent CHD1 deletions in prostate cancers of African American men is associated with rapid disease progression.
Saved in:
| Title: | Frequent CHD1 deletions in prostate cancers of African American men is associated with rapid disease progression. |
|---|---|
| Authors: | Diossy M; Danish Cancer Institute, Copenhagen, Denmark.; Computational Health Informatics Program, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA., Tisza V; Computational Health Informatics Program, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Li H; Center for Prostate Disease Research, Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.; The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc, Bethesda, MD, USA., Sahgal P; Computational Health Informatics Program, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.; The Eli and Edythe L. Broad Institute, Cambridge, MA, USA., Zhou J; Department of Radiation Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Sztupinszki Z; Danish Cancer Institute, Copenhagen, Denmark.; Computational Health Informatics Program, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA., Young D; Center for Prostate Disease Research, Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.; The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc, Bethesda, MD, USA., Nousome D; Center for Prostate Disease Research, Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.; The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc, Bethesda, MD, USA., Kuo C; Center for Prostate Disease Research, Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.; The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc, Bethesda, MD, USA., Jiang J; Center for Prostate Disease Research, Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.; The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc, Bethesda, MD, USA., Chen Y; Center for Prostate Disease Research, Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.; The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc, Bethesda, MD, USA., Ebner R; CytoTest Inc., Rockville, MD, USA., Sesterhenn IA; Joint Pathology Center, Silver Spring, MD, USA., Moncur JT; Joint Pathology Center, Silver Spring, MD, USA., Chesnut GT; Center for Prostate Disease Research, Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD, USA., Petrovics G; Center for Prostate Disease Research, Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.; The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc, Bethesda, MD, USA., Klus GT; Computational Health Informatics Program, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.; Genetics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA., Valcz G; MTA-SE Molecular Medicine Research Group, Hungarian Academy of Sciences, Budapest, 1051, Hungary., Nuzzo PV; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Ribli D; Department of Physics of Complex Systems, Eötvös Loránd University, Budapest, Hungary., Börcsök J; Danish Cancer Institute, Copenhagen, Denmark., Prosz A; Danish Cancer Institute, Copenhagen, Denmark., Krzystanek M; Danish Cancer Institute, Copenhagen, Denmark., Ried T; Genetics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA., Szuts D; Institute of Molecular Life Sciences, HUN-REN Research Centre for Natural Sciences, Budapest, Hungary., Rizwan K; Department of Medicine, Baylor College of Medicine, Houston, TX, USA., Kaochar S; Department of Medicine, Baylor College of Medicine, Houston, TX, USA., Pathania S; Center for Personalized Cancer Therapy, University of Massachusetts, Boston, MA, USA.; Department of Biology, University of Massachusetts, Boston, MA, USA., D'Andrea AD; Department of Radiation Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.; Center for DNA Damage and Repair, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, 02215, USA., Csabai I; Department of Physics of Complex Systems, Eötvös Loránd University, Budapest, Hungary., Srivastava S; Center for Prostate Disease Research, Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.; Department of Biochemistry and Molecular & Cell Biology, Georgetown University School of Medicine, Washington, DC, USA., Freedman ML; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. freedman@broadinstitute.org.; The Eli and Edythe L. Broad Institute, Cambridge, MA, USA. freedman@broadinstitute.org.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. freedman@broadinstitute.org., Dobi A; Center for Prostate Disease Research, Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD, USA. adobi@cpdr.org.; The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc, Bethesda, MD, USA. adobi@cpdr.org., Spisak S; Institute of Molecular Life Sciences, HUN-REN Research Centre for Natural Sciences, Budapest, Hungary. Spisak.sandor@ttk.hu., Szallasi Z; Danish Cancer Institute, Copenhagen, Denmark. Zoltan.Szallasi@childrens.harvard.edu.; Computational Health Informatics Program, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA. Zoltan.Szallasi@childrens.harvard.edu.; 2nd Department of Pathology and Department of Bioinformatics, Semmelweis University, Budapest, Hungary. Zoltan.Szallasi@childrens.harvard.edu. |
| Source: | NPJ precision oncology [NPJ Precis Oncol] 2024 Sep 19; Vol. 8 (1), pp. 208. Date of Electronic Publication: 2024 Sep 19. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Springer Nature Country of Publication: England NLM ID: 101708166 Publication Model: Electronic Cited Medium: Print ISSN: 2397-768X (Print) Linking ISSN: 2397768X NLM ISO Abbreviation: NPJ Precis Oncol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2397-768X |
|---|---|
| DOI: | 10.1038/s41698-024-00705-8 |
